Literature DB >> 30824323

Adventitial Stromal Cells Define Group 2 Innate Lymphoid Cell Tissue Niches.

Madelene W Dahlgren1, Stephen W Jones1, Kelly M Cautivo1, Alexandra Dubinin1, Jorge F Ortiz-Carpena1, Sepideh Farhat1, Kevin S Yu2, Katharine Lee2, Chaoqun Wang3, Anna V Molofsky4, Aaron D Tward2, Matthew F Krummel5, Tien Peng3, Ari B Molofsky6.   

Abstract

Type 2 lymphocytes promote both physiologic tissue remodeling and allergic pathology, yet their physical tissue niches are poorly described. Here, we used quantitative imaging to define the tissue niches of group 2 innate lymphoid cells (ILC2s), which are critical instigators of type 2 immunity. We identified a dominant adventitial niche around lung bronchi and larger vessels in multiple tissues, where ILC2s localized with subsets of dendritic and regulatory T cells. However, ILC2s were most intimately associated with adventitial stromal cells (ASCs), a mesenchymal fibroblast-like subset that expresses interleukin-33 (IL-33) and thymic stromal lymphopoietin (TSLP). In vitro, ASCs produced TSLP that supported ILC2 accumulation and activation. ILC2s and IL-13 drove reciprocal ASC expansion and IL-33 expression. During helminth infection, ASC depletion impaired lung ILC2 and Th2 cell accumulation and function, which are in part dependent on ASC-derived IL-33. These data indicate that adventitial niches are conserved sites where ASCs regulate type 2 lymphocyte expansion and function.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3D-imaging; IL-33; ILC2s; TSLP; Th2 cells; allergic asthma; group 2 innate lymphoid cells; mesenchymal cells; resident lymphocytes; stromal cells; tissue niches; type 2 immunity

Mesh:

Substances:

Year:  2019        PMID: 30824323      PMCID: PMC6553479          DOI: 10.1016/j.immuni.2019.02.002

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  51 in total

1.  Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain.

Authors:  Mélanie Pichery; Emilie Mirey; Pascale Mercier; Emma Lefrancais; Arnaud Dujardin; Nathalie Ortega; Jean-Philippe Girard
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

2.  Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development.

Authors:  Ilia D Vainchtein; Gregory Chin; Frances S Cho; Kevin W Kelley; John G Miller; Elliott C Chien; Shane A Liddelow; Phi T Nguyen; Hiromi Nakao-Inoue; Leah C Dorman; Omar Akil; Satoru Joshita; Ben A Barres; Jeanne T Paz; Ari B Molofsky; Anna V Molofsky
Journal:  Science       Date:  2018-02-01       Impact factor: 47.728

3.  Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33.

Authors:  Wei-Yu Chen; Jaewoo Hong; Joseph Gannon; Rahul Kakkar; Richard T Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-04       Impact factor: 11.205

4.  Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration.

Authors:  Jose E Heredia; Lata Mukundan; Francis M Chen; Alisa A Mueller; Rahul C Deo; Richard M Locksley; Thomas A Rando; Ajay Chawla
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

5.  Context-Dependent Development of Lymphoid Stroma from Adult CD34(+) Adventitial Progenitors.

Authors:  Katarzyna M Sitnik; Kerstin Wendland; Holger Weishaupt; Heli Uronen-Hansson; Andrea J White; Graham Anderson; Knut Kotarsky; William W Agace
Journal:  Cell Rep       Date:  2016-03-03       Impact factor: 9.423

6.  Interleukin-33 and Interferon-γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation.

Authors:  Ari B Molofsky; Frédéric Van Gool; Hong-Erh Liang; Steven J Van Dyken; Jesse C Nussbaum; Jinwoo Lee; Jeffrey A Bluestone; Richard M Locksley
Journal:  Immunity       Date:  2015-06-16       Impact factor: 31.745

Review 7.  Interleukin-33 in Tissue Homeostasis, Injury, and Inflammation.

Authors:  Ari B Molofsky; Adam K Savage; Richard M Locksley
Journal:  Immunity       Date:  2015-06-16       Impact factor: 31.745

8.  A tissue checkpoint regulates type 2 immunity.

Authors:  Steven J Van Dyken; Jesse C Nussbaum; Jinwoo Lee; Ari B Molofsky; Hong-Erh Liang; Joshua L Pollack; Rachel E Gate; Genevieve E Haliburton; Chun J Ye; Alexander Marson; David J Erle; Richard M Locksley
Journal:  Nat Immunol       Date:  2016-10-17       Impact factor: 25.606

9.  Type 2 innate lymphoid cells control eosinophil homeostasis.

Authors:  Jesse C Nussbaum; Steven J Van Dyken; Jakob von Moltke; Laurence E Cheng; Alexander Mohapatra; Ari B Molofsky; Emily E Thornton; Matthew F Krummel; Ajay Chawla; Hong-Erh Liang; Richard M Locksley
Journal:  Nature       Date:  2013-09-15       Impact factor: 49.962

10.  Peripheral PDGFRα+gp38+ mesenchymal cells support the differentiation of fetal liver-derived ILC2.

Authors:  Satoshi Koga; Katsuto Hozumi; Ken-Ichi Hirano; Masaki Yazawa; Tommy Terooatea; Aki Minoda; Takashi Nagasawa; Shigeo Koyasu; Kazuyo Moro
Journal:  J Exp Med       Date:  2018-05-04       Impact factor: 14.307

View more
  98 in total

Review 1.  Regulatory T cells in skin injury: At the crossroads of tolerance and tissue repair.

Authors:  Ian C Boothby; Jarish N Cohen; Michael D Rosenblum
Journal:  Sci Immunol       Date:  2020-05-01

2.  Insulin-like Growth Factor 1 Supports a Pulmonary Niche that Promotes Type 3 Innate Lymphoid Cell Development in Newborn Lungs.

Authors:  Katherine Oherle; Elizabeth Acker; Madeline Bonfield; Timothy Wang; Jerilyn Gray; Ian Lang; James Bridges; Ian Lewkowich; Yan Xu; Shawn Ahlfeld; William Zacharias; Theresa Alenghat; Hitesh Deshmukh
Journal:  Immunity       Date:  2020-02-18       Impact factor: 31.745

3.  Graft IL-33 regulates infiltrating macrophages to protect against chronic rejection.

Authors:  Tengfang Li; Zhongqiang Zhang; Joe G Bartolacci; Gaelen K Dwyer; Quan Liu; Lisa R Mathews; Murugesan Velayutham; Anna S Roessing; Yoojin C Lee; Helong Dai; Sruti Shiva; Martin H Oberbarnscheidt; Jenna L Dziki; Steven J Mullet; Stacy G Wendell; James D Wilkinson; Steven A Webber; Michelle Wood-Trageser; Simon C Watkins; Anthony J Demetris; George S Hussey; Stephen F Badylak; Hēth R Turnquist
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

4.  Tissue-Resident Group 2 Innate Lymphoid Cells Differentiate by Layered Ontogeny and In Situ Perinatal Priming.

Authors:  Christoph Schneider; Jinwoo Lee; Satoshi Koga; Roberto R Ricardo-Gonzalez; Jesse C Nussbaum; Lucas K Smith; Saul A Villeda; Hong-Erh Liang; Richard M Locksley
Journal:  Immunity       Date:  2019-05-22       Impact factor: 31.745

5.  Innate Lymphoid Cells in Airway Inflammation.

Authors:  M Asghar Pasha; Qi Yang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  The interplay between innate lymphoid cells and T cells.

Authors:  Marie Cherrier; Gayetri Ramachandran; Rachel Golub
Journal:  Mucosal Immunol       Date:  2020-07-10       Impact factor: 7.313

7.  Lung group 2 innate lymphoid cells are trained by endogenous IL-33 in the neonatal period.

Authors:  Catherine A Steer; Laura Mathä; Hanjoo Shim; Fumio Takei
Journal:  JCI Insight       Date:  2020-07-23

8.  Stromal cells maintain immune cell homeostasis in adipose tissue via production of interleukin-33.

Authors:  T Mahlakõiv; A-L Flamar; L K Johnston; S Moriyama; G G Putzel; P J Bryce; D Artis
Journal:  Sci Immunol       Date:  2019-05-03

Review 9.  The mesenchymal context in inflammation, immunity and cancer.

Authors:  Vasiliki Koliaraki; Alejandro Prados; Marietta Armaka; George Kollias
Journal:  Nat Immunol       Date:  2020-08-03       Impact factor: 25.606

10.  Fibroblast-Derived IL33 Facilitates Breast Cancer Metastasis by Modifying the Immune Microenvironment and Driving Type 2 Immunity.

Authors:  Ophir Shani; Tatiana Vorobyov; Lea Monteran; Dor Lavie; Noam Cohen; Yael Raz; Galia Tsarfaty; Camila Avivi; Iris Barshack; Neta Erez
Journal:  Cancer Res       Date:  2020-10-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.